Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.6371
+0.0157 (2.53%)
At close: Oct 31, 2025, 4:00 PM EDT
0.6400
+0.0029 (0.46%)
After-hours: Oct 31, 2025, 7:52 PM EDT
Femasys Revenue
Femasys had revenue of $409.27K in the quarter ending June 30, 2025, with 84.78% growth. This brings the company's revenue in the last twelve months to $1.89M, up 98.61% year-over-year. In the year 2024, Femasys had annual revenue of $1.63M with 51.97% growth.
Revenue (ttm)
$1.89M
Revenue Growth
+98.61%
P/S Ratio
8.37
Revenue / Employee
$26,578
Employees
71
Market Cap
27.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.63M | 557.14K | 51.97% |
| Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
| Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
| Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
| Dec 31, 2020 | 1.04M | 108.85K | 11.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
FEMY News
- 16 days ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire
- 7 weeks ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire
- 7 weeks ago - Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand - GlobeNewsWire
- 2 months ago - Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewsWire
- 3 months ago - Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewsWire
- 3 months ago - Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion - GlobeNewsWire
- 4 months ago - Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic - GlobeNewsWire
- 4 months ago - Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control - GlobeNewsWire